• Psychedelics - assisted psychotherapy in Germany


    Despite the huge therapeutic potential, psychedelic-assisted psychotherapy is not part of standard medical care yet. Self-medicating with psychedelics can produce undesired results, but despite that, more and more people feel disappointed with the efficacy of the current treatments and they turn to risky, but potentially more beneficial psychedelic-assisted therapy. The goal of this guide is harm reduction for people, who decided to self-medicate, we don’t encourage possession or consumption of illicit substances even for therapeutic endeavours.

    Book a video consultation Psychedelic integration
Legal status of psychedelics in Germany

If someone cultivates, manufactures, purchases, sells, brings in transit, acquires, or procures, or retains narcotic substances in limited amounts for personal use, prosecutors and courts have the right to refrain from prosecuting or punishing him or her. The definition of a small quantity is not specified in the Act. Instead, the definition of a small amount varies depending on the form of narcotic and is decided by the courts. The Federal Court of Justice determined that the quantity of the active ingredient, not the weight, is important in determining the threshold sum for a limited quantity.

Psilocybe spores are legal for microscopy.

The safest way to obtain psychedelics in Germany

The safest way to obtain psychedelics in Germany is by purchasing the psilocybe spores and a grow kit separately. These are the magic mushrooms, that grow naturally in Germany:

  • Psilocybe germanica

Read the harm reduction guidelines before considering purchasing illicit substances online.



Harm reduction

Other medication

Many people who want to try magic mushrooms are still on medication and want to know if it’s possible to mix their medication with psychedelics. While psilocybin has been shown to effectively treat depression and a variety of other mental health conditions, some antidepressant drugs can interact with the substance in a dangerous or undesirable way.

Interactions between Psilocybin and other medication

Antidepressant drugs may block the therapeutic effects of Psilocybin. If you are on antidepressants, you need to ask your health provider to help you stop taking them before considering psychedelics. SSRIs function by preventing excess serotonin from being cleared from the brain, resulting in a temporary increase in serotonin levels. Although it has been hypothesized that this may contribute to serotonin syndrome in extreme situations, such risks can be reduced with appropriate guidance and medical supervision.  Most common SSRIs are:

  • Citalopram (Celexa, Cipramil)
  • Escitalopram (Lexapro, Cipralex)
  • Fluoxetine (Prozac, Sarafem)
  • Fluvoxamine (Luvox, Faverin)
  • Paroxetine (Paxil, Seroxat)
  • Sertraline (Zoloft, Lustral)

Health conditions that psilocybin may worsen

At first, the findings revealed that people who had used psychedelic drugs were more likely to have mental health issues. However, the researchers took into account a variety of variables that may have influenced the findings, including the participants’ age, gender, and their experience with any highly stressful life event, all of which may influence the likelihood of mental health problems. When those factors were taken into account, the researchers found that people who had used psychedelics were no more likely to develop mental health problems than those who hadn’t used the drugs.

However, it’s not advisable to use psychedelics if you or your family members had psychotic symptoms.

Mushrooms in non-clinical settings are typically eaten orally, either as dried caps and stems or steeped in hot water and drunk as a tea, with a typical dose of 1-2.5 grams, though potency varies depending on the volume. Fresh mushrooms are usually less active than dried mushrooms. There is virtually no chance of accidental deadly overdose with psilocybin mushrooms.

Johns Hopkins study found Psilocybin dosage sweet spot for positive and lasting effects

Researchers found that as higher doses of chemically pure psilocybin were administered, the recorded positive effects increased, but there was also a sharp rise in the negative effects at the very highest dose, which was perhaps unsurprising. At the maximum dose (30 mg/70 kg, p.o. – meaning “per oral” or “by mouth”), 78 percent of the volunteers recorded one of the top five most spiritually important events of their lives, but those experiencing anxiety, stress, and fear episodes increased sixfold, resulting in about a third of those in the study showing signs of psychological distress.

By contrast, only one of the volunteers receiving the second-highest dose (20mg/70 kg, p.o.) reported having negative issues, and all benefited from positive experiences, although with less intensity than at the highest dose. Critically, even the lowest amount used in the study resulted in notable and long-lasting positive changes in the attitudes, behavior, overall satisfaction and spiritual beliefs of the subjects during the period of study. These changes were also noticed by family members and friends.

Psilocybe cubensis

The concentrations of psilocin and psilocybin, as determined by high-performance liquid chromatography, are in the range of 0.14–0.42% and 0.37–1.30% (dry weight) in the whole mushroom, 0.17–0.78%, and 0.44–1.35% in the cap, and 0.09 and 0.30%/0.05–1.27% in the stem, respectively.

Psychedelics-assisted psychotherapy in Germany

The new Medicines Act since 2004 restricts the development of psychedelic therapy in Germany. It created obstacles for researchers and the pharmaceutical industry. Unfortunately, since 2004, experimental studies with any pharmaceuticals have become massively difficult and associated with very high costs. Even large university hospitals cannot pay for the expensive research. As a result, research on all not immediately lucrative pharmaceuticals was stopped, and experimental research projects on pharmaceuticals fell by around 80 percent. Scientific experiments with hallucinogens ceased completely. Without  narrow-minded requirements, Germany would be considerably advanced in research of psychedelics In 2008, for example, scientists were unable to carry out an LSD study for which all permits were in place due to the lack of financial resources. Other EU countries such as Holland or Spain circumvent the regulations by treating psychedelics not as pharmaceuticals but as recreational drugs to be researched. The English used to pretend that the rules don’t exist while being in the EU. And the Swiss, who have been leaders in this field for decades, are not subject to EU directives.